Robinson LB, Fu X, Hashimoto D, et al. - Researchers herein described the incidence of mucocutaneous reactions, such as pruritus, urticaria, and angioedema, after COVID-19 messenger RNA (mRNA) vaccination as well as their recurrence with subsequent vaccination.

• This prospective cohort study included almost 50,000 Mass General Brigham employees who received an mRNA COVID-19 vaccine.

• The first dose of the vaccine was followed by the development of cutaneous reactions in 1.9% of these healthcare employees.

• With more than 600 employees with first-dose cutaneous reactions included, no recurrent cutaneous reactions occurred in 83%.

• Cutaneous reactions developed only after the second dose of the vaccine in an additional 2.3%.

• Women more commonly had development of cutaneous reactions, which was similar to reported local injection site reactions and anaphylaxis after mRNA COVID vaccinations.

• The developed cutaneous reactions after mRNA vaccination include large local reactions, urticaria, and morbilliform reactions.

• The second dose did not induce recurrent reactions in most individuals.

• For revaccination, cutaneous reactions, in isolation, are not a contraindication.